C/Can conceived to combat cancer across global cities

17 January 2017

More than 20 pharma companies have given their backing to C/Can 2025: City Cancer Challenge, a new initiative launched at the World Economic Forum’s (WEC) Annual Meeting in Davos, Switzerland, on Tuesday.

This new city-level initiative has been launched in partnership between the Union for International Cancer Control (UICC), WEC and the World Bank to help country and city leaders to improve the health of their citizens and reduce inequalities in access to quality cancer treatment and care.

"This is a call to action for all sectors to support city governments with populations above one million to respond to the rising epidemic of cancer"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK